22 June 2021 - Written by Nikhil Arora
In this blog, Nik Arora reviews the decision in Moutarde v SIG Logistics to limit the Claimant's success fee in a mesothelioma claim to 27.5%. Q. When is a trial not a trial? ...
17 May 2021 - Written by Richard Gregory
Non-Party Disclosure and CPR 31.17: Sparkes v London Pension Funds Authority & Leigh Academies Trust
A good month for claimants in historic asbestos claims continues. Coming shortly after Scarborough College Ltd v Winter  4 WLUK 352, in which a Show Cause finding in a claimant’s favour was undisturbed on appeal (...
In Scarborough College Ltd v Winter  4 WLUK 352, the High Court considered an appeal by a Defendant against the decision of a Master to enter judgment under CPR PD3D (the show cause procedure). The appeal was dismissed. Cavanagh J held that Judgment had...
19 January 2021 - Written by Thomas Herbert
In a judgment handed down on 18 January 2021 in Head v The Culver Heating Co Ltd  EWCA Civ 34, the Court of Appeal unanimously allowed an appeal against the decision of HHJ Melissa Clarke dismissing the Claimant's 'lost years' claim. The judge had dismi...
18 January 2021 - Written by Jessica Woodliffe
In R (on the application of (1) Aviva Insurance Ltd (2) Swiss Reinsurance Company Ltd) v The Secretary of State for Work and Pensions  EWHC 30 (Admin), Henshaw J dealt with certain consequential matters arising from his ...
14 December 2020 - Written by Abigail Scott
The Industrial Injuries Advisory Council (IIAC) has announced its intention to conduct a review of selected malignant and non-malignant respiratory diseases and their relationships with occupational exposures. The IIAC is the advis...
30 November 2020 - Written by Jessica Woodliffe
Certain Compensation Recovery Unit Payments Declared Incompatible with the European Convention on Human Rights
In R (on the application of (1) Aviva Insurance Ltd (2) Swiss Reinsurance Company Ltd) v The Secretary of State for Work and Pensions  EWHC 3118 (Admin), the Claimants challenged the unintended and onerous consequences of the Compensation Recovery Unit ...
23 October 2020
Following our recent success in the Legal 500 2021, Chambers' expertise in the field of industrial dis...
3 October 2020 - Written by Philip Turton
On 2 October 2020, the American Food & Drug Administration approved a combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co) and ipilimumab (YERVOY, Bristol-Myers Squibb Co) as a first-line treatment for adults with unresectable mesothelioma. Randomi...
Ropewalk Chambers has, over many decades, established a market-leading reputation for detailed and specialist expertise in the field of Industrial Disease litigation.
Whether asbestos, noise, dust, vibration, stress or any other insidious process, including those which are newly emerging, its members have consistently appeared in the leading cases, determining the limits of liability, causation and quantum at first instance and appellate level.
Work is distributed within Chambers to enable Members of Chambers to represent both Claimants and Defendants in this field.
To find out more about our Disease barristers, click here.
Search blog by title or barrister
Subscribe for blog updates
Search by keyword
- Air Pollution
- Bladder Cancer
- Breach of Duty
- Contributory Negligence
- Dupuytren's Contracture
- Dust Diseases
- Expert Evidence
- Fatal Accidents
- Noise-Induced Hearing Loss
- Restoration of Companies
- Noise-Induced Hearing Loss and Medical Causation: NIL on the Slide!
- Abandoning a Single Joint Expert
- They Tried to Make Me File a Budget - I said No, No, No...